. 2022 Feb 4;23(3):330–340. doi: 10.1111/pedi.13320

TABLE 1.

Demographics and baseline outcomes across the multitrajectory groups

Name N (%)	Group 1 (red lines) 624 (12)	Group 2 (green lines) 1988 (39)	Group 3 (blue lines) 1644 (32)	Group 4 (orange lines) 877 (17)
Boys, %	44.1 (40.2; 48.0) −7.4 (−12.5; −2.2)	53.4 (51.2; 55.6) 2.0 (−1.9; 6.0)	42.7 (40.1; 44.9) −9.0 (−13.1; −4.9)	51.4 (48.1; 54.7) Ref.
Migratory background, %	17.3 (14.3; 20.3) −1.3 (−5.2; 2.7)	18.4 (16.7; 20.1) −0.2 (−3.3; 2.9)	16.1 (14.3; 17.8) −2.5 (−5.7; 0.6)	18.6 (16.0; 21.2) Ref.
Age at diabetes onset, years	7.5 (7.3; 7.8) 1.0 (0.7; 1.3)	5.5 (5.3; 5.6) −1.0 (−1.3; −0.8)	6.2 (6.1; 6.4) −0.3 (−0.5; −0.0)	6.5 (6.3; 6.7) Ref.
Age at start of pump therapy, years	14.2 (14.0; 14.5) 1.4 (1.3; 1.8)	11.3 (11.2; 11.4) −1.4 (−1.6; −1.2)	12.5 (12.3; 12.6) −0.2 (−0.5; −0.0)	12.7 (12.5; 12.9) Ref
Baseline HbA1c, %	8.0 (7.9; 8.1) 0.1 (−0.1; 0.2)	7.5 (7.5; 7.6) −0.4 (−0.5; −0.3)	8.1 (8.0; 8.2) 0.2 (0.1; 0.3)	7.9 (7.9; 8.0) Ref.
Baseline HbA1c, mmol/mol	64 (63; 65) 1 (−1; 2)	58 (58; 60) −4 (−5; −3)	65 (64; 66) 2 (1; 3)	63 (63; 64) Ref.
Baseline BMI‐SDS	0.46 (0.39; 0.53) 0.20 (0.11; 0.28)	0.38 (0.35; 0.42) 0.12 (0.05; 0.19)	−0.02 (−0.06; 0.02) −0.29 (−0.36; −0.22)	0.27 (0.21; 0.32) Ref.
Baseline daily insulin dose, IU	74.5 (73.0; 76.1) 33.5 (31.5; 35.5)	38.2 (37.3; 39.0) −2.9 (−4.4; −1.3)	44.9 (44.0; 45.9) 3.9 (2.3; 5.5)	41.0 (39.8; 42.3) Ref.

Name N (%)

Group 1 (red lines) 624 (12)

Group 2 (green lines) 1988 (39)

Group 3 (blue lines) 1644 (32)

Group 4 (orange lines) 877 (17)

Boys, %

44.1 (40.2; 48.0)

−7.4 (−12.5; −2.2)

53.4 (51.2; 55.6)

2.0 (−1.9; 6.0)

42.7 (40.1; 44.9)

−9.0 (−13.1; −4.9)

51.4 (48.1; 54.7)

Ref.

Migratory background, %

17.3 (14.3; 20.3)

−1.3 (−5.2; 2.7)

18.4 (16.7; 20.1)

−0.2 (−3.3; 2.9)

16.1 (14.3; 17.8)

−2.5 (−5.7; 0.6)

18.6 (16.0; 21.2)

Ref.

Age at diabetes onset, years

7.5 (7.3; 7.8)

1.0 (0.7; 1.3)

5.5 (5.3; 5.6)

−1.0 (−1.3; −0.8)

6.2 (6.1; 6.4)

−0.3 (−0.5; −0.0)

6.5 (6.3; 6.7)

Ref.

Age at start of pump therapy, years

14.2 (14.0; 14.5)

1.4 (1.3; 1.8)

11.3 (11.2; 11.4)

−1.4 (−1.6; −1.2)

12.5 (12.3; 12.6)

−0.2 (−0.5; −0.0)

12.7 (12.5; 12.9)

Ref

Baseline HbA1c, %

8.0 (7.9; 8.1)

0.1 (−0.1; 0.2)

7.5 (7.5; 7.6)

−0.4 (−0.5; −0.3)

8.1 (8.0; 8.2)

0.2 (0.1; 0.3)

7.9 (7.9; 8.0)

Ref.

Baseline HbA1c, mmol/mol

64 (63; 65)

1 (−1; 2)

58 (58; 60)

−4 (−5; −3)

65 (64; 66)

2 (1; 3)

63 (63; 64)

Ref.

Baseline BMI‐SDS

0.46 (0.39; 0.53)

0.20 (0.11; 0.28)

0.38 (0.35; 0.42)

0.12 (0.05; 0.19)

−0.02 (−0.06; 0.02)

−0.29 (−0.36; −0.22)

0.27 (0.21; 0.32)

Ref.

Baseline daily insulin dose, IU

74.5 (73.0; 76.1)

33.5 (31.5; 35.5)

38.2 (37.3; 39.0)

−2.9 (−4.4; −1.3)

44.9 (44.0; 45.9)

3.9 (2.3; 5.5)

41.0 (39.8; 42.3)

Ref.

Note: Outcomes and clinical covariates are presented as mean with 95% CI. Differences between estimates with 95% CI were calculated (second line in each cell). Significant differences are marked in bold.